Pyrotinib Combined With Trastuzumab, Dalpiciclibe and Letrozole for HR+/HER2+ Breast Cancer:A Single Arm, Open Label, Phase II Trial
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Dalpiciclib (Primary) ; Letrozole (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 10 Apr 2023 New trial record